"Rationale and Design of two Phase 3 Randomized Controlled Trials (Evolution RMS 1&2) Evaluating the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib in Patients with Relapsing Multiple Sclerosis (4071)." Neurology
94.15 Supplement
(2020):
4071.
Web. 17 May. 2022.
Advertisement